Full details of studies leading to the total synthesis of the teicoplanin aglycon are provided. Key elements of the first generation approach (26 steps from constituent amino acids, 1% overall) include the coupling of an EFG tripeptide precursor to the common vancomycin/teicoplanin ABCD ring system and sequential DE macrocyclization of the 16-membered ring with formation of the diaryl ether via a phenoxide nucleophilic aromatic substitution of an o-fluoronitroaromatic (80%, 3:1 atropisomer diastereoselection) followed by 14-membered FG ring closure by macrolactamization (66%). Subsequent studies have provided a second generation total synthesis which is shorter, more convergent, and highly diastereoselective (22 steps, 2% overall). This was accomplished by altering the order of ring closures such that FG macrolactamization (95%) preceded coupling of the EFG tripeptide to the ABCD ring system and subsequent DE ring closure. Notably, DE macrocyclization via diaryl ether formation on substrate 57, the key intermediate in the latter approach incorporating the intact FG ring system, occurred with exceptional diastereoselection for formation of the natural atropisomer (>10:1, 76%) without problematic C(2)(3) epimerization provided the basicity of the reaction is minimized.
The first total synthesis of the ristocetin aglycon is described employing a modular and highly convergent strategy. An effective 12-step (12% overall) synthesis of the ABCD ring system 3 from its amino acid subunits sequentially features an intramolecular aromatic nucleophilic substitution reaction for formation of the diaryl ether and closure of the 16-membered CD ring system (65%), a respectively diastereoselective (3:1, 86%) Suzuki coupling for installation of the AB biaryl linkage on which the atropisomer stereochemistry can be further thermally adjusted, and an effective macrolactamization (51%) for closure of the 12-membered AB ring system. A similarly effective 13-step (14% overall) synthesis of the 14-membered EFG ring system 4 was implemented employing a room-temperature intermolecular S(N)Ar reaction of an o-fluoronitroaromatic for formation of the FG diaryl ether (69%) and a key macrolactamization (92%) with formation of the amide linking residues 1 and 2. The two key fragments 3 and 4 were coupled, and the remaining 16-membered DE ring system was closed via diaryl ether formation to provide the ristocetin tetracyclic ring system (15 steps, 8% overall) enlisting an unusually facile (25 degrees C, 8 h, DMF, >/=95%) and diastereoselective (>/=15:1) aromatic nucleophilic substitution reaction that benefits from substrate preorganization.
Teicoplanin 1,2 is a complex of five antibiotics isolated from Actinoplanes teichomyceticus that are related to vancomycin [3][4][5][6][7][8] which is enlisted as the drug of last resort for treatment of resistant bacterial infections or for patients allergic to -lactam antibiotics. 6 It is 2-8-fold more potent, possesses a lower toxicity, exhibits a longer half-life in man (40 vs 6 h), and is easier to administer and monitor than vancomycin.Herein we describe the first total synthesis of the teicoplanin aglycon (1). 9-12 Although teicoplanin bears the identical ABCD ring system and the same CDE atropisomer stereochemistry as vancomycin, it contains a DE ring system that lacks the -hydroxy group of the vancomycin E-ring substituted phenylalanine (C 2 residue) and incorporates an especially racemization prone substituted phenylglycine C 3 residue. 13 Most significantly, it contains the additional 14-membered FG ring system not found in vancomycin. Key elements of the approach include sequential DE and FG ring system introductions onto the common vancomycin/teicoplanin ABCD ring system providing a late stage divergent total synthesis of the two classes of glycopeptide antibiotics. The ring systems were introduced enlisting a nucleophilic aromatic substitution reaction of an o-fluoronitroaromatic for macrocyclization and formation of the 16-membered DE diaryl ether and a macrolactamization 14 of the N-terminus amide for closure of the 14-membered FG ring system. With the respective order of closures, the choice of substrates, and the conditions enlisted, no epimerization of the sensitive C 2 3 center was observed.Because of the facile C 2 3 epimerization observed within the confines of the teicoplanin FG ring system, 13 the FG diaryl ether was formed using an intermolecular nucleophilic aromatic substitution reaction with acyclic phenylglycinol substrates incapable of epimerization. Thus, coupling of 2 15 and 3 16 (6 equiv of K 2 CO 3 , 5 equiv of 18-c-6, 0.1 M DMSO, 14 h, 25°C) provided 4 (70%), Scheme 1. Reactions conducted in DMSO were substantially faster than those conducted in DMF and the (1) Parenti, F.; Beretta, G.; Berti, M.; Arioli, V. J. Antibiot. 1978, 31, 276. (2) Hunt, A. H.; Molloy, R. M.; Occolowitz, J. L.; Marconi, G. G.; Debono, M. J. Am. Chem. Soc. 1984, 106, 4891. Barna, J. C. J.; Williams, D. H.; Stone, D. J. M.; Leung, T.-W. C.; Doddrell, D. M. J. Am. Chem. Soc. 1984, 106, 4895. (3) McCormick, M. H.; Stark, W. M.; Pittenger, G. E.; Pittenger, R. C.; McGuire, J. M. Antibiot. Annu. 1955-1956, 606. (4) Harris, C. M.; Kopecka, H.; Harris, T. M. J. Am. Chem. Soc. 1983, 105, 6915. Williamson, M. P.; Williams, D. H. (10) Nicolaou, K. C.; Li, H.; Boddy, C. N. C.; Ramanjulu, J. M.; Yue, T.-Y.; Natarajan, S.; Chu, X.-J.; Bräse, S.; Rübsam, F. Chem. Eur. J. 1999, 5, 2584. Nicolaou, K. C.; Boddy, C. N. C.; Li, H.; Koumbis, A. E.; Hughes, R.; Natarajan, S.; Jain, N. F.; Ramanjulu, J. M.; Bräse, S.; Solomon, M. E. Chem. Eur. J. 1999, 5, 2602. Nicolaou, K. C.; Koumbis, A. E.; Takayanagi, M.; Natarajan, S.; Ja...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.